BIIB Biogen Inc.

Price (delayed)

$288.54

Market cap

$45.68B

P/E Ratio

8.44

Dividend/share

N/A

EPS

$34.19

Enterprise value

$51.13B

Sector: Healthcare
Industry: Drug Manufacturers - General
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Highlights

The P/E is 46% below the 5-year quarterly average of 15.7 and 4.1% below the last 4 quarters average of 8.8
The company's quick ratio rose by 44% QoQ and by 18% YoY
Biogen's debt has increased by 23% from the previous quarter and by 23% YoY
The equity has contracted by 13% YoY and by 10% from the previous quarter

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
158.31M
Market cap
$45.68B
Enterprise value
$51.13B
Valuations
Price to earnings (P/E)
8.44
Price to book (P/B)
4.16
Price to sales (P/S)
3.2
EV/EBIT
7.15
EV/EBITDA
6.53
EV/Sales
3.53
Earnings
Revenue
$14.49B
EBIT
$7.15B
EBITDA
$7.83B
Free cash flow
$6.42B
Per share
EPS
$34.19
Free cash flow per share
$40
Book value per share
$69.3
Revenue per share
$90.21
TBVPS
$101.97
Balance sheet
Total assets
$25.51B
Total liabilities
$14.22B
Debt
$7.84B
Equity
$11.31B
Working capital
$5.05B
Liquidity
Debt to equity
0.69
Current ratio
2.46
Quick ratio
2
Net debt/EBITDA
0.7
Margins
EBITDA margin
54%
Gross margin
88%
Net margin
40.9%
Operating margin
50.9%
Efficiency
Return on assets
22.3%
Return on equity
46.3%
Return on invested capital
41.5%
Return on capital employed
32.4%
Return on sales
49.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$14.49B
Gross profit
$12.74B
Operating income
$7.38B
Net income
$5.93B
Gross margin
88%
Net margin
40.9%
Biogen's net income has increased by 12% YoY
BIIB's operating income is up by 12% year-on-year
Biogen's net margin has increased by 9% YoY
Biogen's operating margin has increased by 9% YoY

Valuation

What is Biogen stock price valuation
P/E
8.44
P/B
4.16
P/S
3.2
EV/EBIT
7.15
EV/EBITDA
6.53
EV/Sales
3.53
The P/E is 46% below the 5-year quarterly average of 15.7 and 4.1% below the last 4 quarters average of 8.8
The EPS has grown by 27% YoY and by 5% from the previous quarter
BIIB's price to book (P/B) is 13% lower than its 5-year quarterly average of 4.8 but 10% higher than its last 4 quarters average of 3.8
The equity has contracted by 13% YoY and by 10% from the previous quarter
The stock's price to sales (P/S) is 32% less than its 5-year quarterly average of 4.7 and 6% less than its last 4 quarters average of 3.4
Biogen's revenue has increased by 3% YoY

Efficiency

How efficient is Biogen business performance
The ROE has grown by 17% YoY and by 4% from the previous quarter
The ROIC has grown by 10% YoY and by 3.5% from the previous quarter
Biogen's return on assets has increased by 9% YoY
The ROS has grown by 3.1% from the previous quarter and by 2.1% YoY

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 79% more than the total liabilities
The company's quick ratio rose by 44% QoQ and by 18% YoY
Biogen's total liabilities has increased by 7% YoY and by 4.7% from the previous quarter
Biogen's debt is 31% less than its equity
The debt to equity has increased by 41% YoY and by 35% from the previous quarter
Biogen's debt has increased by 23% from the previous quarter and by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.